BridgeMD
A study to compare the efficacy of an intradermal and an intramuscular single-visit dosing regimen of the rabies vaccine in adults
EU CTIS ID: 2024-511506-22-00
What this study is testing
To determine if a 4 x 0.1 mL ID or a 1 x 1.0 mL IM priming dose is clinically not inferior to the standard of care schedule as assessed by boostability (percentage of subjects that have rabies antibodies ≥ 0.5 IU/mL) 7 days after booster doses.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ≥18 to ≤60 years of age at time of inclusion
- Willingness to provide written informed consent
- Permanent residency in Belgium during the study period
- Prepared to follow the study schedule
- Willing to use contraception during 1 month after each vaccination (only for women of childbearing potential)
You likely can't join if
- Any vaccination against rabies (memorised or stated in the vaccination certificate)
- Known allergy to one of the components of the vaccines
- Immunocompromised subjects or subjects who take immunosuppressant and/or –stimulant medication
- Planned overseas deployment during the study period
- Ongoing pregnancy or active child wish during the study period (for female subjects)
- Planned vaccination with any inactivated vaccine within 2 weeks before or after each vaccination or with any live attenuated vaccine within 1 month before or after each vaccination
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.